temozolomide has been researched along with Icterus in 2 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide, an oral alkylating agent, is used in the treatment of glioblastoma." | 7.80 | Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma. ( Adeyi, O; Fung, S; Mason, M; Millar, BA, 2014) |
| "Temozolomide, an oral alkylating agent, is used in the treatment of glioblastoma." | 3.80 | Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma. ( Adeyi, O; Fung, S; Mason, M; Millar, BA, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pellini Ferreira, B | 1 |
| Vasquez, J | 1 |
| Carilli, A | 1 |
| Mason, M | 1 |
| Adeyi, O | 1 |
| Fung, S | 1 |
| Millar, BA | 1 |
2 other studies available for temozolomide and Icterus
| Article | Year |
|---|---|
Metastatic Hepatoid Carcinoma of the Pancreas: First Description of Treatment With Capecitabine and Temozolomide.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Biopsy; Capecitabine; Car | 2017 |
Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma.
Topics: Antineoplastic Agents, Alkylating; Biopsy, Needle; Brain Neoplasms; Chemical and Drug Induced Liver | 2014 |